Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nomifensine in parkinsonism

P F Teychenne, D M Park, L J Findley

    Journal of Neurology, Neurosurgery, and Psychiatry
    |December 1, 1976
    PubMed
    Summary

    Nomifensine, an antidepressant, showed moderate therapeutic effects in Parkinsonism patients by enhancing dopamine and norepinephrine. Adverse reactions were observed, similar to levodopa treatments.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Correction to: Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma.

    Cell death and differentiation·2018
    Same author

    Modular peptide-functionalized gold nanorods for effective glioblastoma multicellular tumor spheroid targeting.

    Biomaterials science·2018
    Same author

    Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma.

    Cell death and differentiation·2014
    Same author

    The cardiovascular effects of bromocriptine in Parkinsonism.

    British journal of clinical pharmacology·2012
    Same author

    Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions.

    Cell death & disease·2011
    Same author

    Parkinsonism-physiology and pharmacology.

    British medical journal·2010

    Area of Science:

    • Neuroscience
    • Pharmacology
    • Clinical Neurology

    Background:

    • Parkinsonism is a complex neurological disorder.
    • Current treatments like levodopa have limitations and side effects.
    • Dopaminergic and noradrenergic pathways are implicated in Parkinsonism.

    Purpose of the Study:

    • To evaluate the efficacy and safety of nomifensine in Parkinsonism patients.
    • To assess nomifensine's impact on dopaminergic and noradrenergic transmission in this patient group.

    Main Methods:

    • A double-blind evaluation was conducted on 28 Parkinsonism patients.
    • Most patients were on conventional Parkinsonism medications.
    • Nomifensine was administered at a mean daily dose of 150 mg.

    Main Results:

    • Nomifensine demonstrated a moderate therapeutic effect in Parkinsonism.
    • The mean effective daily dose was 150 mg.
    • Adverse reactions were reported, comparable to those seen with levodopa.

    Conclusions:

    • Nomifensine exhibits potential as a treatment for Parkinsonism.
    • Further research is warranted to explore its therapeutic profile and side effect management.
    • The drug's action on neurotransmitter systems may offer an alternative therapeutic strategy.

    Related Experiment Videos